A nationwide laboratory-based surveillance study of invasive Streptococcus pyogenes infections was conducted in Germany. Invasive isolates (n=586) were obtained between 2003 and 2007. Most isolates were obtained from blood (53.9%) or skin lesions (17.6%). The most common emm types were emm 1 (30.5%), emm 28 (18.3%) and emm 3 (9.6%). Overall, speA was positive in 45.9%, speC in 44.7% and ssa in 14.8% of isolates. SpeA was common in emm type 1 (100%) and emm type 3 (96.4%), whereas speC was often observed in emm type 28 (93.5%). The most frequent clinical manifestations included sepsis (40.1%), necrotizing fasciitis (20.8%) and streptococcal toxic shock syndrome (16.6%). All isolates were susceptible to penicillin G, cefotaxime and levofloxacin. Tetracycline shows the highest rate of resistant or intermediate isolates with 11.6%, followed by clarithromycin (5.5%) and clindamycin (1.2%). The most prominent trend is the reduction of tetracycline-nonsusceptible isolates from 18.6% in 2003 to 8.9% in 2007.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1574-695X.2010.00652.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Relationship Between HSV-1 Serostatus and HSV-2 IgG Confirmation Results Using an Inhibition Assay.
Sex Transm Dis
February 2025
Quest Diagnostics Inc., San Juan Capistrano, CA.
Background: Approximately 2% of HerpeSelect herpes simples virus type 2 (HSV-2) IgG enzyme immunoassay (screen assay) sera-positive samples do not confirm using an HSV-2 IgG inhibition assay. Of these, roughly 1.33% are confirmed negative, and a small proportion (0.
View Article and Find Full Text PDFClinical Snapshot of Group A Streptococcal Isolates from an Australian Tertiary Hospital.
Pathogens
November 2024
Australian Infectious Diseases Research Centre, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4067, Australia.
(Group A , GAS) is a human-restricted pathogen that causes a wide range of diseases from pharyngitis and scarlet fever to more severe, invasive infections such as necrotising fasciitis and streptococcal toxic shock syndrome. There has been a global increase in both scarlet fever and invasive infections during the COVID-19 post-pandemic period. The aim of this study was the molecular characterisation of 17 invasive and non-invasive clinical non-1 GAS isolates from an Australian tertiary hospital collected between 2021 and 2022.
View Article and Find Full Text PDFThe Impact of Pregestational Diabetes on Maternal Morbidity and Mortality: Trends, Challenges, and Future Directions.
Am J Perinatol
December 2024
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Inova Fairfax Medical Campus, Falls Church, Virginia.
Article Synopsis
- * Pregestational diabetes affects 1-2% of pregnancies and is associated with higher risks of severe complications, contributing to 17% of the increase in maternal mortality from 1997 to 2012.
- * There are significant disparities in pregnancy outcomes, particularly affecting non-Hispanic Black women, who are 2.5 times more likely to experience maternal mortality, highlighting the need for targeted research and interventions to improve care and reduce risks.
Group A Streptococcus vulvovaginitis in Spain, 2011-2023: antibiotic resistance and emm-type distribution.
Eur J Clin Microbiol Infect Dis
October 2024
Laboratorio de Microbiología, Hospital Universitari Arnau de Vilanova, Avd Rovira Roure 80, Lleida, 25198, Spain.
An increase in Group A Streptococcus vulvovaginitis was detected in 2023: The average number of cases per year was 13 during 2011-2017. Twenty-five and 27 cases were reported in 2018 and 2019 followed by a decline coinciding with the COVID-19 pandemic. The 2023 increase surpassed previous data.
View Article and Find Full Text PDFPCDH15 dual-AAV gene therapy for deafness and blindness in Usher syndrome type 1F models.
J Clin Invest
October 2024
Department of Neurobiology, Harvard Medical School, Boston, Massachusetts, USA.
Usher syndrome type 1F (USH1F), resulting from mutations in the protocadherin-15 (PCDH15) gene, is characterized by congenital lack of hearing and balance, and progressive blindness in the form of retinitis pigmentosa. In this study, we explore an approach for USH1F gene therapy, exceeding the single AAV packaging limit by employing a dual-adeno-associated virus (dual-AAV) strategy to deliver the full-length PCDH15 coding sequence. We demonstrate the efficacy of this strategy in mouse USH1F models, effectively restoring hearing and balance in these mice.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!